Alternative Medicine is a national magazine with 165,000 subscribers. It is also sold nationwide on newsstands. Its cover story, Nov/Dec, is Kids & Psychiatric Drugs: BIG PHARMA comes to the classroom!
The American Society of Health System Pharmacists reports that the FDA "directed all makers of ADHD stimulants in May to strengthen the wording in the "Warnings" section of the labeling "with regard to serious cardiovascular events and psychiatric events."
Two probing first rate investigative reports document how psychiatry’s treatments are shaped by "opinion leaders" whose professional recommendations are compromised by their substantial, largely undisclosed, financial ties to drug companies.
For almost two decades Eli Lilly has denied that evidence exists demonstrating that its antidepressant Prozac induced violence and suicidality.
This is documented evidence of major medical malpractice.
Informed Consent: The Subject’s Right to Know Here’s what you should ask before you decide to give your informed consent to research. A 1999 report by the Institute of Medicine (IOM), “To Err is Human,” brought to light the magnitude of preventable deaths resulting from medical errors The IOM report…
Our criticism of a high risk, speculative drug experiment conducted on healthy children and adolescents at Yale University’s Psychiatric Institute was validated by a federal investigation: and our criticism is now validated by the principle investigator, Dr. Thomas McGlashan.
The American Psychiatric Association and child psychiatrists in particular are on a collision course:
"I trusted the doctors, I trusted the FDA … and I feel betrayed by both," says Erin Evans, the mother of Rex who was prescribed the ‘atypical’ antipsychotic, Risperdal (risperidone) at age 8.
When the Times refers to an experiment as "bold and controversial" the reporter is sanitizing the fact that the experiment is UNETHICAL—it violates medicine’s cardinal rule "First, do no harm."
The Center for Public Integrity reports that FDA officials circumvent the prohibition on accepting trips from drug and medical device manufacturers.
“Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?” An article in the Schizophrenia Bulletin, by Dr. John Bola that dares to question the validity of the unexamined treatment paradigm in schizophrenia:
